PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26155287-3 2015 This study investigates the association of VDR poly(A) microsatellite variants with 25-hydroxyvitamin D (25(OH)D) serum levels and breast cancer risk. 25-hydroxyvitamin D 84-103 vitamin D receptor Homo sapiens 43-46 24471562-7 2014 MAIN OUTCOMES: Protein and mRNA expressions of CYP27B1, CYP24A1, and vitamin D receptor were measured in term placental tissue and related to 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D, PTH, serum total calcium, IL-6, leptin, and osteoprotegerin measured in maternal serum at midgestation and delivery and in umbilical cord serum at birth. 25-hydroxyvitamin D 142-161 vitamin D receptor Homo sapiens 69-87 25268393-1 2015 BACKGROUND/AIMS: Low 25-hydroxyvitamin D serum levels have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC), and experimental evidence suggested a hepatoprotective role of vitamin D via interaction with hepatic vitamin D receptor (VDR). 25-hydroxyvitamin D 21-40 vitamin D receptor Homo sapiens 265-283 25268393-1 2015 BACKGROUND/AIMS: Low 25-hydroxyvitamin D serum levels have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC), and experimental evidence suggested a hepatoprotective role of vitamin D via interaction with hepatic vitamin D receptor (VDR). 25-hydroxyvitamin D 21-40 vitamin D receptor Homo sapiens 285-288 25354043-2 2014 The discovery that immune cells express the vitamin D receptor and are capable of metabolizing circulating 25-hydroxyvitamin D into its active form, 1,25-dihydroxyvitamin D, has revolutionized the field and suggested a regulatory role on both the innate and adaptive immune systems. 25-hydroxyvitamin D 107-126 vitamin D receptor Homo sapiens 44-62 25070320-0 2014 Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. 25-hydroxyvitamin D 116-135 vitamin D receptor Homo sapiens 41-44 25224407-0 2015 Vitamin D receptor gene polymorphisms (TaqI and ApaI) in relation to 25-hydroxyvitamin D levels and coronary artery disease incidence. 25-hydroxyvitamin D 69-88 vitamin D receptor Homo sapiens 0-18 24582179-1 2014 AIM: 25-hydroxyvitamin D (25OHD) concentrations have been shown to be associated with major clinical outcomes, with a suggestion that individual risk may vary according to common genetic differences in the vitamin D receptor (VDR) gene. 25-hydroxyvitamin D 5-24 vitamin D receptor Homo sapiens 206-224 24582179-1 2014 AIM: 25-hydroxyvitamin D (25OHD) concentrations have been shown to be associated with major clinical outcomes, with a suggestion that individual risk may vary according to common genetic differences in the vitamin D receptor (VDR) gene. 25-hydroxyvitamin D 5-24 vitamin D receptor Homo sapiens 226-229 24732451-2 2014 One recognized mechanism is that the low-serum 25-hydroxyvitamin D (25(OH)D) of VD deficiency reduces intratumoral 25(OH)D conversion to 1alpha,25-dihydroxyvitamin D (1,25D, the hormonal form of VD), compromising 1,25D-VD receptor (VDR) antitumoral actions. 25-hydroxyvitamin D 47-66 vitamin D receptor Homo sapiens 213-230 24732451-2 2014 One recognized mechanism is that the low-serum 25-hydroxyvitamin D (25(OH)D) of VD deficiency reduces intratumoral 25(OH)D conversion to 1alpha,25-dihydroxyvitamin D (1,25D, the hormonal form of VD), compromising 1,25D-VD receptor (VDR) antitumoral actions. 25-hydroxyvitamin D 47-66 vitamin D receptor Homo sapiens 232-235 24790904-7 2014 The three major bone cell types, which are osteoblasts, osteocytes and osteoclasts, can all respond to vitamin D via the classical nuclear vitamin D receptor and metabolize 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D to activate the vitamin D receptor and modulate gene expression. 25-hydroxyvitamin D 173-192 vitamin D receptor Homo sapiens 236-254 23713878-5 2014 The frequency and severity of all of these disorders markedly increase in chronic kidney disease (CKD) because the kidney is essential to maintain serum levels of calcitriol, the most potent endogenous endocrine activator of the vitamin D receptor (VDR), and also of 25-hydroxyvitamin D, for local rather than systemic VDR activation. 25-hydroxyvitamin D 267-286 vitamin D receptor Homo sapiens 229-247 23713878-5 2014 The frequency and severity of all of these disorders markedly increase in chronic kidney disease (CKD) because the kidney is essential to maintain serum levels of calcitriol, the most potent endogenous endocrine activator of the vitamin D receptor (VDR), and also of 25-hydroxyvitamin D, for local rather than systemic VDR activation. 25-hydroxyvitamin D 267-286 vitamin D receptor Homo sapiens 249-252 23713879-1 2014 The activation of vitamin D receptors (VDR) - (including activation by 25-hydroxyvitamin D) - seems to have not only mineral-metabolism beneficial effects but also important extra-skeletal actions. 25-hydroxyvitamin D 71-90 vitamin D receptor Homo sapiens 18-37 23713879-1 2014 The activation of vitamin D receptors (VDR) - (including activation by 25-hydroxyvitamin D) - seems to have not only mineral-metabolism beneficial effects but also important extra-skeletal actions. 25-hydroxyvitamin D 71-90 vitamin D receptor Homo sapiens 39-42 24200978-1 2014 Previous studies have identified several common genetic variants in VDR, GC and CYP2R1 to be associated with circulating levels of 25-hydroxyvitamin D [25(OH)D] and vitamin D deficiency in Western populations. 25-hydroxyvitamin D 131-150 vitamin D receptor Homo sapiens 68-71 23911750-1 2013 Vitamin D activity requires an adequate vitamin D status as indicated by the serum level of 25-hydroxyvitamin D and appropriate expression of genes coding for vitamin D receptor and 25-hydroxyvitamin D 1alpha-hydroxylase, the enzyme which converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. 25-hydroxyvitamin D 182-201 vitamin D receptor Homo sapiens 159-177 23911750-7 2013 Recent research demonstrates that the three major bone cell types have the capability to metabolise 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D to activate the vitamin D receptor and modulate gene expression. 25-hydroxyvitamin D 100-119 vitamin D receptor Homo sapiens 163-181 23276559-10 2012 CONCLUSION: These results suggest that the VDR 1a promoter polymorphisms may not be associated with the risk for PCOS, but are associated with serum 25-hydroxyvitamin D levels. 25-hydroxyvitamin D 149-168 vitamin D receptor Homo sapiens 43-46 23849224-0 2013 Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. 25-hydroxyvitamin D 73-92 vitamin D receptor Homo sapiens 0-18 23849224-9 2013 RESULTS: We found that the amount of VDR binding is correlated with the serum level of 25-hydroxyvitamin D (r = 0.92, P= 0.0005). 25-hydroxyvitamin D 87-106 vitamin D receptor Homo sapiens 37-40 23849224-10 2013 In vivo VDR binding sites are enriched for autoimmune disease associated loci, especially when 25-hydroxyvitamin D levels (25(OH)D) were sufficient (25(OH)D >=75: 3.13-fold, P<0.0001; 25(OH)D <75: 2.76-fold, P<0.0001; 25(OH)D >=75 enrichment versus 25(OH)D <75 enrichment: P= 0.0002). 25-hydroxyvitamin D 95-114 vitamin D receptor Homo sapiens 8-11 23849224-14 2013 Our study further implicates VDR binding as important in gene-environment interactions underlying the development of autoimmunity and provides a biological rationale for 25-hydroxyvitamin D sufficiency being based at 75 nmol/L. 25-hydroxyvitamin D 170-189 vitamin D receptor Homo sapiens 29-32 23289765-4 2013 We show that activation of human monocytes via CD40 ligand (CD40L) and IFN-gamma, alone, and in combination, induces the CYP27b1-hydroxylase, responsible for the conversion of 25-hydroxyvitamin D (25D) to the bioactive 1,25-dihydroxyvitamin D (1,25D), and the vitamin D receptor (VDR). 25-hydroxyvitamin D 176-195 vitamin D receptor Homo sapiens 260-278 23289765-4 2013 We show that activation of human monocytes via CD40 ligand (CD40L) and IFN-gamma, alone, and in combination, induces the CYP27b1-hydroxylase, responsible for the conversion of 25-hydroxyvitamin D (25D) to the bioactive 1,25-dihydroxyvitamin D (1,25D), and the vitamin D receptor (VDR). 25-hydroxyvitamin D 176-195 vitamin D receptor Homo sapiens 280-283 23150009-3 2012 OBJECTIVE: To investigate whether common variation within genes encoding the vitamin D-binding protein, megalin, cubilin, CYP27B1, CYP24A1, and the vitamin D receptor (VDR) modify associations of low 25-hydroxyvitamin D with major clinical outcomes. 25-hydroxyvitamin D 200-219 vitamin D receptor Homo sapiens 168-171 23150009-8 2012 RESULTS: Interactions between 5 single-nucleotide polymorphisms and low 25-hydroxyvitamin D concentration were identified in the discovery phase and 1 involving a variant in the VDR gene replicated in independent meta-analysis. 25-hydroxyvitamin D 72-91 vitamin D receptor Homo sapiens 178-181 23150009-11 2012 CONCLUSION: Known associations of low 25-hydroxyvitamin D with major health outcomes may vary according to common genetic differences in the vitamin D receptor. 25-hydroxyvitamin D 38-57 vitamin D receptor Homo sapiens 141-159 22213340-8 2012 Under multivariate analysis with 25-hydroxyvitamin D as well as other 8 covariates including disease duration, carriers of vitamin D receptor FokICC genotype had a milder form of Parkinson"s disease: odds ratio, 0.32; 95% confidence interval, 0.16 to 0.66, P = 0.002. 25-hydroxyvitamin D 33-52 vitamin D receptor Homo sapiens 123-141 22564539-5 2012 We also examined the association of VDR protein expression with circulating serum levels of 25-hydroxyvitamin D(3) (25-D(3)) and 1,25-D(3). 25-hydroxyvitamin D 92-111 vitamin D receptor Homo sapiens 36-39 22388612-2 2012 The expression of both vitamin D receptor and 1alpha-hydroxylase in cells of the immune system and in both osteoblasts and osteoclasts makes it possible that 25-hydroxyvitamin D could play an important role in both inflammation and bone metabolism acting in a autocrine and/or paracrine way in these patients. 25-hydroxyvitamin D 158-177 vitamin D receptor Homo sapiens 23-41 22193171-0 2012 Association between plasma 25-hydroxyvitamin D and colorectal adenoma according to dietary calcium intake and vitamin D receptor polymorphism. 25-hydroxyvitamin D 27-46 vitamin D receptor Homo sapiens 110-128 22193171-6 2012 Of note, the association between plasma 25-hydroxyvitamin D levels and colorectal adenoma was modified by the TaqI polymorphism of the VDR gene (P(interaction) = 0.03) but not by dietary calcium intake (P(interaction) = 0.93). 25-hydroxyvitamin D 40-59 vitamin D receptor Homo sapiens 135-138 21640757-1 2011 Considering that the vitamin D receptor as well as the 1-alpha-hydroxylase enzyme that converts 25-hydroxyvitamin D (25(OH)D) to its active form 1,25-dihydroxyvitamin D have been found in tissues throughout the body, it is likely that vitamin D is important for more than the calcium balance. 25-hydroxyvitamin D 96-115 vitamin D receptor Homo sapiens 21-39 22213318-6 2012 Recent evidence indicates that 25-hydroxyvitamin D [25(OH)D] and its analogs can bind to VDR as agonists, without converting them to 1alpha,25(OH)(2)D or the corresponding 1alpha-hydroxylated metabolites, to modulate gene expressions that will lead to cell growth arrest and other antitumor activities. 25-hydroxyvitamin D 31-50 vitamin D receptor Homo sapiens 89-92 22536765-6 2012 In vitro human bone cell cultures and animal model studies indicate that 25-hydroxyvitamin D can be metabolised to 1,25-dihydroxyvitamin D by each of the major bone cells to activate VDR and modulate gene expression to reduce osteoblast proliferation and stimulate osteoblast and osteoclast maturation. 25-hydroxyvitamin D 73-92 vitamin D receptor Homo sapiens 183-186 25018912-4 2011 The kidney is the main site for the conversion of 25-hydroxyvitamin D (25D) to circulating calcitriol, and therefore essential for the health benefits of endocrine VDR activation. 25-hydroxyvitamin D 50-69 vitamin D receptor Homo sapiens 164-167 20947319-2 2010 More recently, the discovery that many human tissues and cells, which do not directly participate in mineral ion homeostasis, express the vitamin D receptor (VDR) and are able to convert the circulating pro-hormone 25-hydroxyvitamin D in its active form, 1,25-dihydroxyvitamin D, has provided new insights into the biological function of this peculiar endocrine system. 25-hydroxyvitamin D 215-234 vitamin D receptor Homo sapiens 138-156 21941448-1 2011 INTRODUCTION: The discovery that many tissues express the vitamin D receptor and are able to transform the 25-hydroxyvitamin D into 1,25-dihydroxyvitamin D (active metabolite) has led to the hypothesis that vitamin D could have a role in the pathogenesis and prevention of diabetes mellitus. 25-hydroxyvitamin D 107-126 vitamin D receptor Homo sapiens 58-76 21537045-1 2011 PURPOSE: Data suggest that circulating 25-hydroxyvitamin D [25(OH)D] interacts with the vitamin D receptor (VDR) to decrease proliferation and increase apoptosis for some malignancies, although evidence for prostate cancer is less clear. 25-hydroxyvitamin D 39-58 vitamin D receptor Homo sapiens 88-106 21537045-1 2011 PURPOSE: Data suggest that circulating 25-hydroxyvitamin D [25(OH)D] interacts with the vitamin D receptor (VDR) to decrease proliferation and increase apoptosis for some malignancies, although evidence for prostate cancer is less clear. 25-hydroxyvitamin D 39-58 vitamin D receptor Homo sapiens 108-111 20947319-2 2010 More recently, the discovery that many human tissues and cells, which do not directly participate in mineral ion homeostasis, express the vitamin D receptor (VDR) and are able to convert the circulating pro-hormone 25-hydroxyvitamin D in its active form, 1,25-dihydroxyvitamin D, has provided new insights into the biological function of this peculiar endocrine system. 25-hydroxyvitamin D 215-234 vitamin D receptor Homo sapiens 158-161 19758194-2 2009 Another SNP of the VDR gene, Fokl (rs10735810), has been associated with serum levels of 25-hydroxyvitamin D [25(OH)D]. 25-hydroxyvitamin D 89-108 vitamin D receptor Homo sapiens 19-22 19944755-0 2010 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. 25-hydroxyvitamin D 0-19 vitamin D receptor Homo sapiens 39-57 19944755-1 2010 25-Hydroxyvitamin D(3) 1alpha-hydroxylase encoded by CYP27B1 converts 25-hydroxyvitamin D(3) into 1alpha,25-dihydroxyvitamin D(3), a vitamin D receptor ligand. 25-hydroxyvitamin D 70-89 vitamin D receptor Homo sapiens 133-151 19944755-9 2010 In conclusion, 25-hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand with gene regulatory and anti-proliferative properties. 25-hydroxyvitamin D 15-34 vitamin D receptor Homo sapiens 54-72 20393752-4 2010 Most tissues in the body have a vitamin D receptor and the enzymatic machinery to convert "nutritional" 25-hydroxyvitamin D to the active form 1,25-dihydroxyvitamin D; it is estimated that 3% of the human genome is regulated by the vitamin D endocrine system. 25-hydroxyvitamin D 104-123 vitamin D receptor Homo sapiens 32-50 19018272-0 2009 Maternal 25-hydroxyvitamin D concentration and offspring birth size: effect modification by infant VDR genotype. 25-hydroxyvitamin D 9-28 vitamin D receptor Homo sapiens 99-102 21088715-0 2009 Frequency of fokI and taqI polymorphism of vitamin D receptor gene in Indian population and its association with 25-hydroxyvitamin D levels. 25-hydroxyvitamin D 113-132 vitamin D receptor Homo sapiens 43-61 18285415-7 2008 The BB VDR genotype was associated with lower serum 25-hydroxyvitamin D levels in both patients and controls and with severity of rickets. 25-hydroxyvitamin D 52-71 vitamin D receptor Homo sapiens 7-10 18936471-3 2008 PATIENTS AND METHODS: We evaluated the relationship between circulating 25-hydroxyvitamin D levels; VDR polymorphisms, including Cdx-2 G>A (rs11568820), FokI C>T (rs10735810), and BsmI C>T (rs144410); and overall survival among patients with advanced NSCLC. 25-hydroxyvitamin D 72-91 vitamin D receptor Homo sapiens 100-103 16955631-5 2006 25(OH)D has higher affinity for vitamin D binding protein (VDBP) than 1,25-dihydroxyvitamin D; whereas, 1,25-dihydroxyvitamin D has higher affinity for the vitamin D receptor (VDR) than 25-hydroxyvitamin D. 25-hydroxyvitamin D 186-205 vitamin D receptor Homo sapiens 156-174 16563471-2 2006 After hydroxylation in the liver into 25-hydroxyvitamin D (25(OH)D) and kidney into 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite can enter the cell, bind to the vitamin D-receptor and subsequently to a responsive gene such as that of calcium binding protein. 25-hydroxyvitamin D 38-57 vitamin D receptor Homo sapiens 176-194 17129633-1 2007 OBJECTIVE: To evaluate the influence of ApaI, BsmI and TaqI polymorphisms of the VDR gene and HLA-DQB1* alleles in type 1 diabetic children and to assess their possible relationship with circulating levels of 25-hydroxyvitamin D(3), auto-antibodies, and INFgamma/TGFbeta1 cytokines levels in Chilean cases and controls. 25-hydroxyvitamin D 209-228 vitamin D receptor Homo sapiens 81-84 33806559-4 2021 The aim of this work was to reveal the effects of VDR gene ApaI rs7975232, BsmI rs1544410, TaqI rs731236, FokI rs2228570, and Cdx2 rs11568820 variants on bone mineral density (BMD), 25-hydroxyvitamin D level, and OP risk in Belarusian women. 25-hydroxyvitamin D 182-201 vitamin D receptor Homo sapiens 50-53 15585637-1 2004 The 25-hydroxyvitamin D(3) (25-OH-D(3)) is a nontoxic and low-affinity vitamin D receptor (VDR)-binding metabolic precursor of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]. 25-hydroxyvitamin D 4-23 vitamin D receptor Homo sapiens 71-89 15585637-1 2004 The 25-hydroxyvitamin D(3) (25-OH-D(3)) is a nontoxic and low-affinity vitamin D receptor (VDR)-binding metabolic precursor of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]. 25-hydroxyvitamin D 4-23 vitamin D receptor Homo sapiens 91-94 11179736-1 2001 Human colorectal cancer cells not only express the nuclear vitamin D receptor (VDR) but are also endowed with 25-hydroxy-vitamin D(3)-1alpha-hydroxylase activity and therefore are able to produce the specific ligand for the VDR, the hormonally active steroid 1alpha,25-dihydroxyvitamin D(3) (1alpha,25(OH)(2)D(3)). 25-hydroxyvitamin D 110-130 vitamin D receptor Homo sapiens 224-227 35379049-7 2022 Lower relative vitamin D receptor mRNA expression in papillary thyroid cancer was associated with low serum 25-hydroxyvitamin D level. 25-hydroxyvitamin D 108-127 vitamin D receptor Homo sapiens 15-33 35196255-3 2022 Thus, serum 25-hydroxyvitamin D (25D) can be converted to hormonal 1,25-dihydroxyvitamin D (1,25D) within immune cells, and then interact with VDR and promote transcriptional and epigenomic responses in the same or neighbouring cells. 25-hydroxyvitamin D 12-31 vitamin D receptor Homo sapiens 143-146 34578994-10 2021 Particular VDR genotypes were associated with 25-hydroxyvitamin-D levels, and the mechanism of this association should be further investigated. 25-hydroxyvitamin D 46-65 vitamin D receptor Homo sapiens 11-14 35379049-9 2022 Conclusions: An association between decreased vitamin D receptor protein expression and advanced stage papillary thyroid cancer, and a correlation between low vitamin D receptor mRNA expression with low serum 25-hydroxyvitamin D level was observed. 25-hydroxyvitamin D 209-228 vitamin D receptor Homo sapiens 159-177 32174704-7 2020 Based on our findings, the relationship between the VDR polymorphism, the serum concentration of 25-hydroxyvitamin D and the susceptibility to Leishmania tropica infection, remains unclear requiring further in-depth studies. 25-hydroxyvitamin D 97-116 vitamin D receptor Homo sapiens 52-55 33279474-4 2021 The demonstration that the vitamin D receptor (VDR) is ubiquitously, expressed combined with increasing observational data supporting a relationship between the level of 25-hydroxy-vitamin D in the serum and chronic metabolic disorders, cardiovascular disease and neoplasms, have led to its redefinition as a steroid hormone and the proposal of its use in preventing and/or treating those diseases. 25-hydroxyvitamin D 170-190 vitamin D receptor Homo sapiens 27-45 33279474-4 2021 The demonstration that the vitamin D receptor (VDR) is ubiquitously, expressed combined with increasing observational data supporting a relationship between the level of 25-hydroxy-vitamin D in the serum and chronic metabolic disorders, cardiovascular disease and neoplasms, have led to its redefinition as a steroid hormone and the proposal of its use in preventing and/or treating those diseases. 25-hydroxyvitamin D 170-190 vitamin D receptor Homo sapiens 47-50 33259013-4 2020 Cytochrome enzymes CYP27B1 and CYP24A1 that perform the final conversion of the circulating form of vitamin D, 25-hydroxyvitamin D (25-OHD) to the active VDR ligand, 1a,25-dihydroxyvitamin D and the catabolism of it to inactive 24,25-dihydroxyvitamin D, respectively, are also expressed in breast cancer tissues. 25-hydroxyvitamin D 111-130 vitamin D receptor Homo sapiens 154-157 32093012-7 2020 VDR rs10783219 might therefore be a genetic modulator of increasing 25-hydroxyvitamin D concentrations. 25-hydroxyvitamin D 68-87 vitamin D receptor Homo sapiens 0-3 31086078-0 2019 25-Hydroxyvitamin D Inhibits Hepatitis C Virus Production in Hepatocellular Carcinoma Cell Line by a Vitamin D Receptor-Independent Mechanism. 25-hydroxyvitamin D 0-19 vitamin D receptor Homo sapiens 101-119 32368685-3 2019 This study aims to evaluate the association of five SNPs in the VDR gene with 25-hydroxyvitamin D (25[OH]D) levels in patients with at least one CVD risk factor. 25-hydroxyvitamin D 78-97 vitamin D receptor Homo sapiens 64-67 30321335-2 2019 Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites, including 1,25(OH)2D, the ligand for the vitamin D receptor (VDR). 25-hydroxyvitamin D 30-49 vitamin D receptor Homo sapiens 114-132 30321335-2 2019 Vitamin D is the precursor of 25-hydroxyvitamin D and other metabolites, including 1,25(OH)2D, the ligand for the vitamin D receptor (VDR). 25-hydroxyvitamin D 30-49 vitamin D receptor Homo sapiens 134-137 30833174-0 2019 Vitamin D Receptor in Breast Cancer Tissues and Its Relation to Estrogen Receptor Alpha (ER-alpha) Gene Expression and Serum 25-hydroxyvitamin D Levels in Egyptian Breast Cancer Patients: A Case-control Study. 25-hydroxyvitamin D 125-144 vitamin D receptor Homo sapiens 0-18 30833174-1 2019 INTRODUCTION: This study aimed to explore the role of vitamin D receptor (VDR) in breast cancer tissues and its relation to serum 25-hydroxyvitamin D [25(OH)D] levels and estrogen receptor alpha (ER-alpha) gene expression in patients with breast cancer. 25-hydroxyvitamin D 130-149 vitamin D receptor Homo sapiens 54-72 30833174-1 2019 INTRODUCTION: This study aimed to explore the role of vitamin D receptor (VDR) in breast cancer tissues and its relation to serum 25-hydroxyvitamin D [25(OH)D] levels and estrogen receptor alpha (ER-alpha) gene expression in patients with breast cancer. 25-hydroxyvitamin D 130-149 vitamin D receptor Homo sapiens 74-77 28799838-3 2017 In this study, we aimed to investigate the FokI polymorphism in the VDR gene in Egyptian children and adolescents with SLE, to determine whether this polymorphism could be a genetic marker for cSLE susceptibility or disease activity and we also measured the serum level of 25-hydroxyvitamin D [25(OH) D] to assess its relation to such polymorphism. 25-hydroxyvitamin D 273-292 vitamin D receptor Homo sapiens 68-71 30984586-0 2019 Association of Vitamin D Receptor Gene Polymorphisms and Serum 25-Hydroxy Vitamin D Levels in Vitiligo - A Case-control Study. 25-hydroxyvitamin D 63-83 vitamin D receptor Homo sapiens 15-33 30184513-0 2019 Vitamin D receptor gene polymorphisms modify the association of serum 25-hydroxyvitamin D levels with handgrip strength in the elderly in Northern China. 25-hydroxyvitamin D 70-89 vitamin D receptor Homo sapiens 0-18 30039758-2 2018 The active form of vitamin D, 25-hydroxyvitamin D, binds to vitamin D receptor (VDR) controlling the synthesis of many different proteins. 25-hydroxyvitamin D 30-49 vitamin D receptor Homo sapiens 60-78 30039758-2 2018 The active form of vitamin D, 25-hydroxyvitamin D, binds to vitamin D receptor (VDR) controlling the synthesis of many different proteins. 25-hydroxyvitamin D 30-49 vitamin D receptor Homo sapiens 80-83 30319189-0 2018 Association of Vitamin D Receptor (FokI and BsmI) Gene Polymorphism with Bone Mineral Density and Their Effect on 25-Hydroxyvitamin D Level in North Indian Postmenopausal Women with Osteoporosis. 25-hydroxyvitamin D 114-133 vitamin D receptor Homo sapiens 15-33 29738868-0 2018 BSMI single nucleotide polymorphism in vitamin D receptor gene is associated with decreased circulatory levels of serum 25-hydroxyvitamin D among micro and macrovascular complications of type 2 diabetes mellitus. 25-hydroxyvitamin D 120-139 vitamin D receptor Homo sapiens 39-57 30024533-1 2018 OBJECTIVES: To explore the relationship among the vitamin D receptor (VDR) gene polymorphisms, serum 25-hydroxyvitamin D levels, and vitiligo. 25-hydroxyvitamin D 101-120 vitamin D receptor Homo sapiens 50-68 30024533-1 2018 OBJECTIVES: To explore the relationship among the vitamin D receptor (VDR) gene polymorphisms, serum 25-hydroxyvitamin D levels, and vitiligo. 25-hydroxyvitamin D 101-120 vitamin D receptor Homo sapiens 70-73 28739347-5 2018 METHODS: This hospital-based case-control study was designed to study the association between 25-hydroxy vitamin D (25[OH]D) levels and the vitamin D receptor (VDR) gene polymorphism with diabetes and to evaluate their roles as risk factors for diabetes. 25-hydroxyvitamin D 94-114 vitamin D receptor Homo sapiens 140-158 28739347-5 2018 METHODS: This hospital-based case-control study was designed to study the association between 25-hydroxy vitamin D (25[OH]D) levels and the vitamin D receptor (VDR) gene polymorphism with diabetes and to evaluate their roles as risk factors for diabetes. 25-hydroxyvitamin D 94-114 vitamin D receptor Homo sapiens 160-163 29530503-12 2018 VDR FokI T allele had lower 25-hydroxyvitamin D level that may predispose to sepsis hazards. 25-hydroxyvitamin D 28-47 vitamin D receptor Homo sapiens 0-3 29175129-11 2018 CONCLUSION: We observed associations between VDR, GC, and CYP27B1 variants and maternal 25-hydroxyvitamin D concentration. 25-hydroxyvitamin D 88-107 vitamin D receptor Homo sapiens 45-48 28555324-4 2017 Among risk factors recognized, deficiency in 25-hydroxyvitamin D [25(OH)D], already acknowledged as involved in calcium homeostasis, pathogenesis of cardiovascular, oncological, infective and immunity diseases, could predispose to the development of both type 1 and 2 diabetes, modifying the activity of pancreatic beta-cells vitamin D (VD) receptor. 25-hydroxyvitamin D 45-64 vitamin D receptor Homo sapiens 326-349 28469103-0 2017 Association between Serum 25-hydroxy Vitamin D Concentration and TaqI Vitamin D Receptor Gene Polymorphism among Jordanian Females with Breast Cancer. 25-hydroxyvitamin D 26-46 vitamin D receptor Homo sapiens 70-88 30258921-2 2017 The aim of this study is to analyze the associations between Vitamin D receptor (VDR) gene polymorphism, serum 25-hydroxy vitamin D, metabolic and inflammatory biomarkers in Egyptian obese women. 25-hydroxyvitamin D 111-131 vitamin D receptor Homo sapiens 61-79 30258921-2 2017 The aim of this study is to analyze the associations between Vitamin D receptor (VDR) gene polymorphism, serum 25-hydroxy vitamin D, metabolic and inflammatory biomarkers in Egyptian obese women. 25-hydroxyvitamin D 111-131 vitamin D receptor Homo sapiens 81-84 28700743-2 2017 Deficiency of 25-hydroxyvitamin D and single nucleotide polymorphisms (SNPs) in the vitamin D receptor (VDR) gene may increase the risk of TB disease and decrease culture conversion rates in drug susceptible TB. 25-hydroxyvitamin D 14-33 vitamin D receptor Homo sapiens 84-102 31149190-5 2017 Aim: To examine the relationship between Cdx-2 polymorphism (rs17883968), the methylation status of VDR"s promoter and serum levels of 25-hydroxyvitamin D in male infertility. 25-hydroxyvitamin D 135-154 vitamin D receptor Homo sapiens 100-103 27771345-0 2017 The association between vitamin D receptor polymorphisms and serum 25-hydroxyvitamin D levels with ulcerative colitis in Chinese Han population. 25-hydroxyvitamin D 67-86 vitamin D receptor Homo sapiens 24-42 27771345-3 2017 In the current study, we examined the association between VDR polymorphisms and serum level of 25-hydroxyvitamin D [25(OH)D] with UC in Chinese Han population. 25-hydroxyvitamin D 95-114 vitamin D receptor Homo sapiens 58-61 27682437-0 2017 Weekday sunlight exposure, but not vitamin D intake, influences the association between vitamin D receptor genotype and circulating concentration 25-hydroxyvitamin D in a pan-European population: the Food4Me study. 25-hydroxyvitamin D 146-165 vitamin D receptor Homo sapiens 88-106 27861345-3 2016 To date, only a few studies concerned the association of the VDR gene polymorphisms with childhood-onset SLE.In this study, we aimed to investigate the BsmI polymorphisms in the VDR gene, for the first time in Egyptian children and adolescents with SLE, to determine whether this polymorphism could be a marker of susceptibility to or severity of SLE and we also measured the serum level of 25-hydroxyvitamin D (25[OH] D) to assess its relation to such polymorphism.This was a case-control study including 100 patients with SLE and matched with age, sex, and ethnicity and 100 healthy controls. 25-hydroxyvitamin D 391-410 vitamin D receptor Homo sapiens 178-181 26970179-0 2016 Cdx-2 polymorphism in Vitamin D Receptor gene was associated with serum 25-hydroxyvitamin D levels, bone mineral density and fracture in middle-aged and elderly Chinese women. 25-hydroxyvitamin D 72-91 vitamin D receptor Homo sapiens 22-40 26970179-1 2016 The aim of the current study was to examine the relationship between Cdx-2 polymorphism in the promoter region of the VDR gene and serum 25-hydroxyvitamin D (25(OH)D) levels, bone mineral density (BMD) and fracture in Chinese population. 25-hydroxyvitamin D 137-156 vitamin D receptor Homo sapiens 118-121 26934299-7 2016 These findings are relevant to humans, because we discovered that the mechanism of VDR regulation of Inhibitor of differentiation 1 (ID1) is conserved in human BCa cells, and there is a negative correlation between serum 25-hydroxyvitamin D levels and the level of ID1 in primary tumors from patients with BCa. 25-hydroxyvitamin D 221-240 vitamin D receptor Homo sapiens 83-86 26770250-0 2015 Comment to "Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: Association with Susceptibility to Breast Cancer". 25-hydroxyvitamin D 71-90 vitamin D receptor Homo sapiens 12-30 27155524-0 2016 Association of polymorphisms in the vitamin D receptor gene and serum 25-hydroxyvitamin D levels in children with autism spectrum disorder. 25-hydroxyvitamin D 70-89 vitamin D receptor Homo sapiens 36-54